Osteoarthritis
Conditions
Interventions
DRUG: Orforglipron(Other Name: (LY3502970))
Administered orally
DRUG: Placebo
Administered orally
(Study Arms)
Experimental: Orforglipron (GZT1)
Participants will receive orforglipron orally
Sponsors
Masaki Takeshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Have a body mass index (BMI) of 27 kilograms per square meter (kg/m2) or higher at screening - Have tried at least once to lose weight through diet but were unsuccessful - Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee
Exclusion criteria
Exclusion criteria: - Have gained or lost more than 11 pounds within 90 days prior to screening - Have had a surgery for obesity or plan to have one in the next 18 months - Have an active knee infection - Have type 1 diabetes, type 2 diabetes, or any other type of diabetes - Have had a recent heart condition or New York Heart Association Functional Classification Class IV congestive heart failure - Have used any glucagon-like peptide-1 (GLP-1) receptor agonist medication within 180 days of screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [ Time Frame: Baseline, Week 72 | — |
Countries
Canada, China, Germany, India, Japan, Mexico, Spain, United States
Contacts
Public ContactTrial Guide Call Center
Eli Lilly Japan K.K.
Outcome results
None listed